Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized controlled trial of escitalopram versus placebo for patients with irritable bowel syndrome and panic disorder

Next Previous
Trial Profile

Randomized controlled trial of escitalopram versus placebo for patients with irritable bowel syndrome and panic disorder

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Irritable bowel syndrome; Panic disorder
  • Focus Therapeutic Use

Most Recent Events

  • 12 Mar 2012 Planned end date changed from 30 Sep 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
  • 12 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
  • 12 Mar 2012 New source identified and integrated (NCT01551225; ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top